TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04133610

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampling using digene HC2 DNA Collection Device
Description: All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampling using Evalyn Brush
Description: All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
Study: NCT03935386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Multi-layered Compression dressing
Description: Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)
Description: Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
Study: NCT02181530

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) is being administered as part of this study.
Study: NCT01561118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle-Ergometer Training
Description: Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis.
Study: NCT01141894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed haemodynamic treatment
Description: Treatment by fluids and Dobutamine to attain fixed haemodynamic goal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine fluid treatment
Description: Protocol guided fluid treatment used in the clinical routine
Study: NCT02357212

Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary angiography
Description: invasive procedure performed to determine coronary anatomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adenosine stress test
Description: non-invasive procedure to determine area of cardiac ischemia
Study: NCT03606759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weekly assessment ajusted
Description: Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)
Study: NCT04143802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03012321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Study: NCT03921268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
Study: NCT01561118

Intervention type: OTHER
Group type: OTHER
Intervention: Bicycle-Ergometer Training
Description: Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis.
Study: NCT00678379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine (1%) + bupivacaine (0.5%)
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)
Study: NCT03921268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
Study: NCT03721380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
Study: NCT01735539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g EAA bolus
Description: Oral; in aqueous solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g EAA bolus
Description: Oral; in aqueous solution
Study: NCT03012321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT00113334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-510
Description: 100 mg subcutaneously twice daily
Study: NCT05444777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine was given prior to wound closure.

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine Hydrochloride
Description: Ketamine was given prior to wound closure.
Study: NCT03441789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Enstilar foam applied to affected areas daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: vehicle foam applied to affected areas once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otezla
Description: Otezla 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Otezla
Description: Otezla 30mg
Study: NCT03508882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 100Unit/Vial (Product)
Description: Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 100Unit/Vial (Product)
Description: Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution for Injection
Description: The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution for Injection
Description: The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
Study: NCT03661749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clean catch
Description: clean catch technique applied to collect urine for PR/CR ratio
Study: NCT00678379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline
Study: NCT01735539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 x 3.75g Mixed EAA Pulses
Description: Oral; in aqueous solution
Study: NCT00678379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)
Description: Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)
Study: NCT01361607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Study: NCT03661749

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean catch
Description: clean catch technique applied to collect urine for PR/CR ratio
Study: NCT01361607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (GA-0034)
Study: NCT01611168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Algorithms
Description: subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
Study: NCT04013022

Intervention type: BEHAVIORAL
Intervention: Exercise History
Description: The groups will be divided based on their exercise history

Intervention type: BEHAVIORAL
Intervention: Exercise History
Description: The groups will be divided based on their exercise history

Intervention type: BEHAVIORAL
Intervention: Exercise History
Description: The groups will be divided based on their exercise history

Intervention type: BEHAVIORAL
Intervention: Exercise History
Description: The groups will be divided based on their exercise history
Study: NCT05680207

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes self- management education (DSME) program
Description: We offered a two-hour course each week, comprising of two sessions of lectures (40 minutes each), two breaks (10 min each) and interactive session (20 min). In the interactive session, patients could communicate with each other in groups or raise any questions to the investigators.
Study: NCT00575328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root
Description: 3g/day of Maca Root for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo provided by research pharmacy daily for 12 weeks.
Study: NCT00179452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study: NCT04051632

Intervention type: DEVICE
Intervention: Medtronic 670G insulin pump
Description: * percent of patients who continue to use Medtronic 670G over time~* impact of 670G on glycemic control: hemoglobin A1c, time in range
Study: NCT00404586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW784568X
Description: GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW784568X
Description: GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW784568X
Description: GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo to GW784568X as aqueous nasal spray.
Study: NCT00068237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salivary gland transfer
Description: Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy
Description: Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
Study: NCT01004120

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bimuno
Description: 5.5g daily intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 5.5g daily intake
Study: NCT01735539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4 x 3.75g Mixed EAA Pulses
Description: Oral; in aqueous solution

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15g EAA Bolus supplemented with 3g Arginine
Description: Oral; in aqueous solution
Study: NCT02995603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-X patient rotation
Description: Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
Study: NCT00033254

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo conventional radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo conventional radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03114254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.
Study: NCT01793064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Intervention (AI)
Description: Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Intervention (SI)
Description: Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website.
Study: NCT00201006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Description: Biweekly group behavioral counseling sessions conducted in a face-to-face format

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Biweekly telephone counseling sessions conducted in a one-on-one format

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mail contact
Description: Biweekly written newsletters with weight management advice delivered via U.S. mail
Study: NCT03869775

Intervention type: DEVICE
Intervention: perfusion index monitor
Description: perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor

Intervention type: DEVICE
Intervention: perfusion index monitor
Description: perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor

Intervention type: DEVICE
Intervention: perfusion index monitor
Description: perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor

Intervention type: DIAGNOSTIC_TEST
Intervention: ewing test
Description: ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: ewing test
Description: ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
Study: NCT02523313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Placebo
Description: Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double Placebo Control
Description: Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
Study: NCT03348891

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor biopsy specimens and blood samples
Description: Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor biopsy specimens and blood samples
Description: Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
Study: NCT00919243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 1 mg/kg/day with a maximum dose of 60 mg/day given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol
Description: allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
Study: NCT03239379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNZ132-1-40
Description: Injectable peptide antagonist of IL-2, IL-9 and IL-15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT02126293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat blood and urine tests
Study: NCT00814372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: over-encapsulated to match MBX-102 and placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: greater than or equal to 1500 mg/kg day
Study: NCT01629251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Description: Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop insulin delivery
Description: Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.